曲美他嗪辅助治疗冠心病伴心力衰竭的疗效及安全性分析

发表时间：2014-06-09 浏览次数：815次

引用：

胡文义,冯胜红,任静,冯永生.曲美他嗪辅助治疗冠心病伴心力衰竭的疗效及安全性分析[J].吉林医学,2014,35(15).3219-3220

关键词：

曲美他嗪；冠心病；心力衰竭

作者：

胡文义,冯胜红,任静,冯永生.

作者单位：

四川省达州市中西医结合医院心血管内科，四川达州 635000

出版年份：

2014

期刊页数：

3219-3220

收录者：

知网,万方

摘要：

目的：探讨曲美他嗪辅助治疗冠心病合并心力衰竭的临床效果及安全性。方法：将冠心病心力衰竭患者79例按不同治疗方法分为试验组（42例，对症治疗加美托洛尔加曲美他嗪）与对照组（37例，对症治疗加美托洛尔），对两组治疗效果进行综合比较。结果：①试验组治疗总有效率为90.48%，明显高于对照组（72.97%）（P＜0.05）；②治疗3个月后，试验组LEVDD、LEVF、 LEVSD、6 min步行距离明显优于对照组（P＜0.05）；③两组不良反应发生率比较差异无统计学意义（P＞0.05）。结论：曲美他嗪用于临床辅助治疗冠心病合并心力衰竭效果显著，安全性可靠，值得临床推广应用。 Objective To investigate the clinical effects and security about trimetazidine in the accessorial treatment of coronary disease with cardiac failure.Methods 79 cases coronary disease with cardiac failure patients were divided into experimental group(42 cases,were given symptomatic treatment+metoprolol+trimetazidine) and control group(37 cases,were given symptomatic treatment+metoprolol),the efficacy of two groups were compared.Results:①The total efficiency of experimental group(90.48%),which was higher than that of control group(72.97%)(P ＜0.05);②After 3 months of treatment,the LEVDD,LEVF,LEVSD,6 min walking-distance of experimental group were better than that of control group(P＜0.05);③There were no statistically significant difference in incidence of adverse reactions between two groups.Conclusion There is a significant effects on in accessorial treating coronary disease with cardiac failure,which has a high security,and it is worthy of clinical widely.

阅读全文